The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
about
Advances in rheumatology: new targeted therapeuticsIntra-thoracic rheumatoid arthritis: Imaging spectrum of typical findings and treatment related complicationsTumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.gp130 at the nexus of inflammation, autoimmunity, and cancer.Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size.Etanercept in psoriasis: the evidence of its therapeutic impact.Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients.Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve.Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoidAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryThe therapeutic potential of RNA interference.Current imaging strategies in rheumatoid arthritisBiologic therapies for inflammatory eye disease.Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.Malnutrition and infection: an update.Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort.Update on the natural history and systemic treatment of psoriasis.Treatment of severe psoriasis with infliximab.Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewVaccination with cytokines in autoimmune diseases.Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive.Infliximab in the treatment of rheumatoid arthritisBiological drugs targeting the immune response in the therapy of psoriasisComparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.Novel immunobiologics for psoriasis.Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE).Selective TNF-α inhibitor-induced injection site reactions.Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.Emerging role of endosomal toll-like receptors in rheumatoid arthritisEfficacy and safety of etanercept in chronic immune-mediated disease.Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs.Infection risk associated with anti-TNF-α agents: a review.Developing of Granulomatosis with Polyangiitis during Etanercept Therapy.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
P2860
Q21093257-DB21F243-6CC2-4E16-BDDE-7E6465B68EF7Q26799587-147DA605-59F9-455D-871C-A9A5C455A1EBQ33328963-0FF75BD8-D07F-43FE-8A95-E2C3AEDAA7DEQ34378756-E4A3E2E5-45DB-4C72-B366-C971A75BD733Q34413235-29855CF0-C643-4C8D-B0D4-3C8FAF436732Q34445142-ECEBA00A-48C1-4B81-ADCD-3A7A08CD9C9BQ34450544-E6F60C44-F4EA-4AD9-9379-3BC43B5E52AEQ35176993-E785F9C1-726D-4BE3-A484-E0FB10319BD4Q35776382-1CC35320-2E5A-4C40-8278-DEF22541AC90Q35940690-C1FE22BD-D7A3-4D35-A248-1B67825A42EFQ35953319-5645E686-4F55-4243-BC9C-1040AD7DC221Q36024297-E9887EC9-D3A5-42F5-A85F-E7AA037D54AAQ36237868-0487CED2-9316-4B79-8181-553C4E01F703Q36337258-81284C41-FB13-4762-8EF5-83A70183CB0EQ36501675-82647C18-D7BA-4F63-9300-5AC4C3F340AEQ36677345-72727AD6-4B0F-401F-9921-28DDD3E2741FQ36965020-4CB19D69-5747-4ED7-B499-EBEED8381F3FQ36984088-05F7785B-64CE-48C2-91FD-A90A98F986A8Q37081486-968E0AE5-A82C-4963-A07B-F610284BCA85Q37098135-4D4475C5-FB06-4332-9E15-439280B472F6Q37158791-40B19300-F66A-421B-88E5-AEF859C698ACQ37165366-493411AC-0F5E-461F-8A76-FB2857B3349CQ37221167-B8EBB650-4228-429A-BBA6-5746BEF5C79DQ37271950-AB8FF3EE-B86C-44FA-8DB7-FFEC3E789F24Q37303230-FC747545-D12F-440C-8893-BF1EB5404868Q37307801-B413AE34-8393-4D5E-9091-69DD800E3AC1Q37474169-08591A50-7124-4FC7-AEF7-98313AD9830FQ37664478-2CB0798B-1953-4D6E-A604-8A76F4A33F14Q37709460-5889A531-4D15-43DB-AA27-EB961406B39CQ38075021-1E8E47AA-1823-485D-AE8B-51FBD0BDDEDDQ38107072-C223D8B7-32AB-4C29-A7C1-3A48A370EDA7Q38166663-68FDF021-7F6C-48BB-B2F5-7E6BCE9E4CB5Q38175430-944213B7-7432-40BD-87DF-B777F8E84861Q38182971-9264E442-A7E3-45F2-AD81-10CB603EDDEFQ38198080-2CF6D734-EF10-4E89-B457-A7BC9671237FQ38258624-0F62F3CB-53FE-46CC-BBC0-F5C5D2B082B8Q38303453-73FF7118-BF3F-40DB-9144-E29D83AA9432Q38335718-43DED4DE-D470-4113-A0CD-0527330C5238Q38514582-4CBB59D9-53DE-4C40-81A0-0A74034AA1CDQ38631012-4BC77714-A1DD-4E10-90D9-1E09DF3ECC77
P2860
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@ast
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@en
type
label
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@ast
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@en
prefLabel
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@ast
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@en
P2093
P1476
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
@en
P2093
David E Yocum
Kathryn F Hobbs
Marc C Hochberg
Mark G Lebwohl
Scott E Plevy
P304
P356
10.1016/J.SEMARTHRIT.2004.11.006
P577
2005-06-01T00:00:00Z